<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382588</url>
  </required_header>
  <id_info>
    <org_study_id>4321</org_study_id>
    <nct_id>NCT02382588</nct_id>
  </id_info>
  <brief_title>Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis</brief_title>
  <official_title>A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Gancyclovir Gel (Zirgan) Versus 0.3% Hypromellose Gel (Genteal Gel; Placebo) for the Treatment of Herpes Zoster Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the
      treatment of herpes zoster keratitis. Half the patients will receive the study drug while the
      other half of the patients will receive the placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with herpes zoster keratitis will be enrolled in the study. All patients will
      receive oral anti-viral medication as a standard-of-care therapy. The patients will be
      randomized into two groups and given either the study drug or the placebo at the time of
      enrollment. The patients will come for weekly visits during which slit lamp photograph of the
      dendrite will be taken. At week 2, if the dendrite has not healed the drug will by unmasked
      and rescue therapy will be given. the patients will be examined at week 1, 2, and 3 or until
      resolution occurs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing based on weekly slitlamp photographs</measure>
    <time_frame>2 weeks</time_frame>
    <description>Based on weekly slitlamp photographs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Herpes Zoster Keratitis</condition>
  <arm_group>
    <arm_group_label>Gancyclovir gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypromellose gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gancyclovir gel</intervention_name>
    <description>0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.</description>
    <arm_group_label>Gancyclovir gel</arm_group_label>
    <other_name>zirgan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypromellose gel</intervention_name>
    <description>0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.</description>
    <arm_group_label>hypromellose gel</arm_group_label>
    <other_name>genteal gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 and above

          -  have not been on gancyclovir gel or any other form of topical antiviral therapy for
             the past month

          -  able and willing to attend subsequent follow-up visits

        Exclusion Criteria:

          -  Associated retinitis

          -  patients who are allergic to gancyclovir

          -  patients who will require systemic or intra-vitreal gancyclovir therapy

          -  patients who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert S Feder, MD, MBA</last_name>
    <phone>312-695-8150</phone>
    <email>r-feder@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Seddon</last_name>
    <phone>312-695-0252</phone>
    <email>nreinhol@nm.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert S Feder, MD, MBA</last_name>
      <phone>312-695-8150</phone>
      <email>r-feder@northwestrn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Seddon</last_name>
      <phone>312-695-0252</phone>
      <email>nreinhol@nm.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008 Feb;115(2 Suppl):S3-12. doi: 10.1016/j.ophtha.2007.10.009. Review.</citation>
    <PMID>18243930</PMID>
  </reference>
  <reference>
    <citation>Ostler HB, Thygeson P. The ocular manifestations of herpes zoster, varicella, infectious mononucleosis, and cytomegalovirus disease. Surv Ophthalmol. 1976 Sep-Oct;21(2):148-59.</citation>
    <PMID>185734</PMID>
  </reference>
  <reference>
    <citation>Liesegang TJ. Corneal complications from herpes zoster ophthalmicus. Ophthalmology. 1985 Mar;92(3):316-24.</citation>
    <PMID>3873048</PMID>
  </reference>
  <reference>
    <citation>Trousdale MD, Nesburn AB, Willey DE, Taaid H. Efficacy of BW759 (9-[[2-hydroxy-1(hydroxymethyl)ethoxy]methyl]guanine) against herpes simplex virus type 1 keratitis in rabbits. Curr Eye Res. 1984 Aug;3(8):1007-15.</citation>
    <PMID>6333319</PMID>
  </reference>
  <reference>
    <citation>Villarreal EC. Current and potential therapies for the treatment of herpes-virus infections. Prog Drug Res. 2003;60:263-307. Review.</citation>
    <PMID>12790345</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Robert Feder</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Keratitis</mesh_term>
    <mesh_term>Herpes Zoster Ophthalmicus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Once the study is completed study results will be shared with the study subjects.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

